Semen parameters in testicular tumor patients before orchiectomy: What is the impact of testicular tumor stage and histology?
https://doi.org/10.4081/aiua.2024.12238
Accepted: December 29, 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Purpose: To evaluate the influence of testicular cancer histology and stage on sperm parameters in cryopreserved samples collected prior to orchiectomy.
Materials and methods: We conducted a retrospective analysis of tumor histology, stage and sperm parameters of patients who underwent pre-orchiectomy sperm cryopreservation for testicular cancer between March 2010 and March 2023. The World Health Organization (WHO) 2010 sperm reference values were used to identify patients with subnormal semen parameters and to further categorize patients by sperm alteration. Localized disease was classified as Stage I, while metastatic disease encompassed Stages II and III. Continuous variables were compared using t-test or Mann Whitney U test, and categorical variables using Chi-square and Fishers exact test.
Results: A total of 64 patients was identified, 48 (75%) classified as stage I and 16 (25%) classified as stage II/III. No difference was found in semen parameters between patients with seminoma and patients with non-seminoma germ cell tumor (NSGCT). Patients with stage II/III disease had significantly lower percentages of progressive motility (36% vs 53%, p=0.021) and total motility (60% vs 69%, p=0.015) than stage I patients. When categorizing by sperm alterations according to WHO 2010 reference values, patients with stage II/III disease had significantly higher proportions of asthenozoospermia (38% vs 15%, p=0.048) and teratozoospermia (63% vs 31%, p=0.027) than stage I patients. Elevated tumor markers were not associated with sperm abnormalities.
Conclusions: Patients with metastatic testicular cancer present with worse sperm quality than patients with localized disease. Sperm cryopreservation should be offered to all patients with testicular cancer, and especially emphasized in patients with metastatic disease.
Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine. 2018; 97:e12390. DOI: https://doi.org/10.1097/MD.0000000000012390
Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2015;33:623-31. DOI: https://doi.org/10.1007/s00345-014-1361-y
Gurney JK, Florio AA, Znaor A, et al. International Trends in the Incidence of Testicular Cancer: Lessons from 35 Years and 41 Countries. Eur Urol. 2019;76:615-23. DOI: https://doi.org/10.1016/j.eururo.2019.07.002
Djaladat H, Burner E, Parikh PM, et al. The Association Between Testis Cancer and Semen Abnormalities Before Orchiectomy: A Systematic Review. J Adolesc Young Adult Oncol. 2014;3:153-9. DOI: https://doi.org/10.1089/jayao.2014.0012
Parekh N V, Lundy SD, Vij SC. Fertility considerations in men with testicular cancer. Transl Androl Urol. 2020;9:S14-23. DOI: https://doi.org/10.21037/tau.2019.08.08
Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010;16:231-45. DOI: https://doi.org/10.1093/humupd/dmp048
Moody JA, Ahmed K, Yap T, et al. Fertility managment in testicular cancer: the need to establish a standardized and evidence-based patient-centric pathway. BJU Int. 2019;123:160-72. DOI: https://doi.org/10.1111/bju.14455
Badia RR, Patel A, Chertack N, et al. Impact of testicular cancer stage on semen parameters in patients before orchiectomy. Urol Oncol. 2023;41:151.e11. DOI: https://doi.org/10.1016/j.urolonc.2022.11.004
Ho GT, Gardner H, DeWolf WC, et al. Influence of testicular carcinoma on ipsilateral spermatogenesis. J Urol. 1992;148:821-5. DOI: https://doi.org/10.1016/S0022-5347(17)36732-0
Ho GT, Gardner H, Mostofi K, et al. The effect of testicular nongerm cell tumors on local spermatogenesis. Fertil Steril. 1994;62:162-6. DOI: https://doi.org/10.1016/S0015-0282(16)56833-2
Choy JT, Wiser HJ, Bell SW, et al. Predictors of spermatogenesis in orchiectomy specimens. Urology. 2013;81:288-92. DOI: https://doi.org/10.1016/j.urology.2012.10.038
Shoshany O, Shtabholtz Y, Schreter E, et al. Predictors of spermatogenesis in radical orchiectomy specimen and potential implications for patients with testicular cancer. Fertil Steril. 2016;106:70-4. DOI: https://doi.org/10.1016/j.fertnstert.2016.03.012
Coward RM, Kovac JR, Smith RP, Lipshultz LI. Fertility Preservation in Young Men Treated for Malignancies: Options for Precancer Treatment. Sex Med Rev. 2013;1:123-34. DOI: https://doi.org/10.1002/smrj.13
Peluso G, Tisato V, Singh AV, et al. Semen Cryopreservation to Expand Male Fertility in Cancer Patients: Intracase Evaluation of Semen Quality. J Pers Med. 2023;13:1654. DOI: https://doi.org/10.3390/jpm13121654
Said TM, Tellez S, Evenson DP, Del Valle AP. Assessment of sperm quality, DNA integrity and cryopreservation protocols in men diagnosed with testicular and systemic malignancies. Andrologia. 2009;41:377-82. DOI: https://doi.org/10.1111/j.1439-0272.2009.00941.x
Kumar K, Lewis S, Vinci S, et al. Evaluation of sperm DNA quality in men presenting with testicular cancer and lymphoma using alkaline and neutral Comet assays. Andrology. 2018;6:230-5. DOI: https://doi.org/10.1111/andr.12429
Petersen PM, Skakkebaek NE, Rørth M, Giwercman A. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. J Urol. 1999;61:822-6. DOI: https://doi.org/10.1097/00005392-199903000-00023
Rives N, Perdrix A, Hennebicq S, et al. The semen quality of 1158 men with testicular cancer at the time of cryopreservation: results of the French National CECOS Network. J Androl. 2012;33:1394-401. DOI: https://doi.org/10.2164/jandrol.112.016592
Emmanuel A, Kanthabalan A, Alexander C, et al. Expedited Radical Orchidectomy for Testicular Cancer: Compromising Fertility Outcomes Without Oncological Benefit? Eur Urol. 2021;80:766-7. DOI: https://doi.org/10.1016/j.eururo.2021.08.025
Puscheck E, Philip PA, Jeyendran RS. Male fertility preservation and cancer treatment. Cancer Treat Rev. 2004;30:173-80. DOI: https://doi.org/10.1016/j.ctrv.2003.07.005
Brydøy M, Fosså SD, Klepp O, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst. 2005;97:1580-8. DOI: https://doi.org/10.1093/jnci/dji339
Brydøy M, Fosså SD, Klepp O, et al. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. Br J Cancer. 2012;107:1833-9. DOI: https://doi.org/10.1038/bjc.2012.471
Lampe H, Horwich A, Norman A, et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol. 1997;15:239-45. DOI: https://doi.org/10.1200/JCO.1997.15.1.239
Fraietta R, Spaine DM, Bertolla RP, et al. Individual and seminal characteristics of patients with testicular germ cell tumors. Fertil Steril. 2010;94:2107-12. DOI: https://doi.org/10.1016/j.fertnstert.2009.12.021
Halstuch D, Shtabholtz Y, Neufeld S, et al. The absence of spermatogenesis in radical orchiectomy specimen is associated with advanced-stage nonseminomatous testicular cancer. Urol Oncol. 2021;39:838.e15. DOI: https://doi.org/10.1016/j.urolonc.2021.08.004
Patrikidou A, Cazzaniga W, Berney D, et al. European Association of Urology Guidelines on Testicular Cancer: 2023 Update. Eur Urol. 2023;84:289-301. DOI: https://doi.org/10.1016/j.eururo.2023.04.010
Ping P, Gu BH, Li P, et al. Fertility outcome of patients with testicular tumor: before and after treatment. Asian J Androl. 2014;16:107-11. DOI: https://doi.org/10.4103/1008-682X.122194
Sonnenburg DW, Brames MJ, Case-Eads S, Einhorn LH. Utilization of sperm banking and barriers to its use in testicular cancer patients. Support Care Cancer. 2015;23:2763-8. DOI: https://doi.org/10.1007/s00520-015-2641-9
Magelssen H, Haugen TB, von Düring V, et al. Twenty years experience with semen cryopreservation in testicular cancer patients: who needs it? Eur Urol. 2005;48:779-85. DOI: https://doi.org/10.1016/j.eururo.2005.05.002
Gilbert K, Nangia AK, Dupree JM, et al. Fertility preservation for men with testicular cancer: Is sperm cryopreservation cost effective in the era of assisted reproductive technology? Urol Oncol. 2018;36:92.e1. DOI: https://doi.org/10.1016/j.urolonc.2017.11.002
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
